RxDoctor Payments Data

Peter Hendricks

Family · Littleton, CONPI 1528752706

Payments from drug & device makers

$1,784in general payments, 2019–2025

Across 55 payments — averaging $32.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$349
  • Alnylam Pharmaceuticals Inc.$275
  • AstraZeneca$183
  • Abbott$175
  • Lexicon Pharmaceuticals, Inc.$167
  • Scpharmaceuticals Inc.$151
  • plus $484 from 10 others

What the payments were for

  • Food & beverage$1,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,784 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$54,045
Medicare patients
350
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$44,707
EntrestoSacubitril/Valsartan30$30,523
EliquisApixaban30$28,735
FarxigaDapagliflozin Propanediol11$13,784
Bumetanide19$1,080
Spironolactone97$645
Metoprolol Succinate73$618
Torsemide35$564
Valsartan22$461
Rosuvastatin Calcium32$455
Nitroglycerin14$314
Potassium Chloride24$282
Losartan Potassium34$270
Furosemide69$269
Atorvastatin Calcium33$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$87$44,70767 claims
NovartisEntresto$87$30,52330 claims
AstraZenecaFarxiga$183$13,78411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.

Other family in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →